Literature DB >> 23325550

Identification of DNA-dependent protein kinase catalytic subunit as a novel interaction partner of lymphocyte enhancer factor 1.

Atsushi Shimomura1, Akihiko Takasaki, Ryuji Nomura, Nobuhiro Hayashi, Takao Senda.   

Abstract

Lymphocyte enhancer factor 1 (LEF1), a member of the LEF/T-cell-specific factor (TCF) family of the high mobility group domain transcription factors, acts downstream in canonical Wnt signaling. Aberrant transactivation of LEF1 contributes to the tumorigenesis of colonic neoplasms, sebaceous skin tumors, and lymphoblastic leukemia. LEF1-associated proteins are crucial for regulating its transcriptional activity. In this study, glutathione-S-transferase pull-down assay and mass spectrometry enabled identification of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a novel interaction partner for LEF1. The interaction between LEF1 and DNA-PKcs was confirmed using in vivo co-immunoprecipitation. Furthermore, double immunofluorescence observations showed that LEF1 and DNA-PKcs colocalized in the nuclei of colon adenocarcinoma cell lines. Identification of the interaction between LEF1 and DNA-PKcs may provide clues for a novel therapy for cancer treatment as well as for understanding LEF1-mediated transcriptional regulation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23325550     DOI: 10.1007/s00795-012-0002-z

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  29 in total

1.  Interaction between Wnt and TGF-beta signalling pathways during formation of Spemann's organizer.

Authors:  M Nishita; M K Hashimoto; S Ogata; M N Laurent; N Ueno; H Shibuya; K W Cho
Journal:  Nature       Date:  2000-02-17       Impact factor: 49.962

Review 2.  The life and death of DNA-PK.

Authors:  Spencer J Collis; Theodore L DeWeese; Penelope A Jeggo; Antony R Parker
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

3.  ZIC2-dependent transcriptional regulation is mediated by DNA-dependent protein kinase, poly(ADP-ribose) polymerase, and RNA helicase A.

Authors:  Akira Ishiguro; Maki Ideta; Katsuhiko Mikoshiba; David J Chen; Jun Aruga
Journal:  J Biol Chem       Date:  2007-01-23       Impact factor: 5.157

4.  Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.

Authors:  Alejandro Gutierrez; Takaomi Sanda; Wenxue Ma; Jianhua Zhang; Ruta Grebliunaite; Suzanne Dahlberg; Donna Neuberg; Alexei Protopopov; Stuart S Winter; Richard S Larson; Michael J Borowitz; Lewis B Silverman; Lynda Chin; Stephen P Hunger; Catriona Jamieson; Stephen E Sallan; A Thomas Look
Journal:  Blood       Date:  2010-02-01       Impact factor: 22.113

5.  Human sebaceous tumors harbor inactivating mutations in LEF1.

Authors:  Hikaru Takeda; Stephen Lyle; Alexander J F Lazar; Christos C Zouboulis; Ian Smyth; Fiona M Watt
Journal:  Nat Med       Date:  2006-03-26       Impact factor: 53.440

6.  beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation.

Authors:  C Liu; Y Kato; Z Zhang; V M Do; B A Yankner; X He
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

7.  Armadillo/beta-catenin signals in the nucleus--proof beyond a reasonable doubt?

Authors:  Mariann Bienz; Hans Clevers
Journal:  Nat Cell Biol       Date:  2003-03       Impact factor: 28.824

8.  Crystal structure of a beta-catenin/axin complex suggests a mechanism for the beta-catenin destruction complex.

Authors:  Yi Xing; Wilson K Clements; David Kimelman; Wenqing Xu
Journal:  Genes Dev       Date:  2003-11-04       Impact factor: 11.361

9.  Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis.

Authors:  Maralice E Conacci-Sorrell; Tamar Ben-Yedidia; Michael Shtutman; Elena Feinstein; Paz Einat; Avri Ben-Ze'ev
Journal:  Genes Dev       Date:  2002-08-15       Impact factor: 11.361

10.  Sequence-specific DNA binding by Ku autoantigen and its effects on transcription.

Authors:  W Giffin; H Torrance; D J Rodda; G G Préfontaine; L Pope; R J Hache
Journal:  Nature       Date:  1996-03-21       Impact factor: 49.962

View more
  4 in total

Review 1.  From inception to output, Tcf1 and Lef1 safeguard development of T cells and innate immune cells.

Authors:  Farrah C Steinke; Hai-Hui Xue
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

2.  Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose.

Authors:  Maria Peiris-Pagès; Federica Sotgia; Michael P Lisanti
Journal:  Oncoscience       Date:  2015-08-24

3.  High expression of PRKDC promotes breast cancer cell growth via p38 MAPK signaling and is associated with poor survival.

Authors:  Yan Zhang; Wei-Kang Yang; Guo-Ming Wen; Hongping Tang; Chuan-An Wu; Yan-Xia Wu; Zhi-Liang Jing; Min-Shan Tang; Guang-Long Liu; Da-Zhou Li; Yan-Hua Li; Yong-Jian Deng
Journal:  Mol Genet Genomic Med       Date:  2019-09-12       Impact factor: 2.183

4.  Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.

Authors:  Zongxiang Zhou; Manishha Patel; Nicholas Ng; Mindy H Hsieh; Anthony P Orth; John R Walker; Serge Batalov; Jennifer L Harris; Jun Liu
Journal:  BMC Cancer       Date:  2014-12-13       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.